Lilly Alimta begins Phase III for small-cell lung cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly is enrolling patients in a Phase III global, open-label study evaluating Alimta (pemetrexed) in extensive-stage small-cell lung cancer. The trial, known as GALES (Global Analysis of Pemetrexed in SCLC Extensive Stage) will enroll roughly 1,820 subjects to assess the antifolate in combination with carboplatin compared to etoposide in combination with carboplatin. Overall survival is the primary endpoint. The study will use pharmacogenomic analysis to assess potential biological characteristics to match possible better responders to the treatment. On Nov. 13, the U.K. National Institute for Health & Clinical Excellence recommended against the use of Alimta for non-small cell lung cancer, based upon results of survival data compared to less expensive treatment options...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.